Treatment of Cystic Fibrosis (CF) in patients with CFTR mutations who are responders in the organoid assay research hub

Testing new medicine for adults with Cystic Fibrosis who do not have access to the currently available CFTR-modulating drugs due to genetic mutations

This clinical trial tests a new three-in-one medicine for adults with cystic fibrosis who have rare genetic mutations. These patients cannot access currently approved treatments. Researchers are checking whether this daily combination of capsules can safely improve lung health after promising results in laboratory tests using patient cell samples.